MedPath

Janssen-Cilag SpA

Janssen-Cilag SpA logo
🇮🇹Italy
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.janssen.com/italy

Clinical Trials

14

Active:0
Completed:14

Trial Phases

3 Phases

Phase 2:1
Phase 3:2
Phase 4:1

Drug Approvals

9

SFDA:8
PHILIPPINES:1

Drug Approvals

Benadryl One

Approval Date
Jul 14, 2025
PHILIPPINES

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 3
2 (50.0%)
Phase 2
1 (25.0%)
Phase 4
1 (25.0%)

A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag

Completed
Conditions
Pulmonary Arterial Hypertension
Interventions
First Posted Date
2020-09-28
Last Posted Date
2025-06-25
Lead Sponsor
Janssen-Cilag S.p.A.
Target Recruit Count
372
Registration Number
NCT04567602
Locations
🇮🇹

Generale Regionale F. Miulli, Acquaviva Delle Fonti, Italy

🇮🇹

A.O. Universitaria Ospedali Riuniti di Ancona, Ancona, Italy

🇮🇹

Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italy

and more 27 locations

A Study to Describe Routine Treatment Pathways in Participants With Major Depression and Active Suicidal Ideation With Intent in Italy

Completed
Conditions
Depressive Disorder, Major
Suicidal Ideation
First Posted Date
2020-07-09
Last Posted Date
2025-04-27
Lead Sponsor
Janssen-Cilag S.p.A.
Target Recruit Count
136
Registration Number
NCT04463108
Locations
🇮🇹

Ospedale S Francesco d Assisi, Oliveto Citra, Italy

🇮🇹

ASST Spedali Civili Brescia, Brescia, Italy

🇮🇹

Ospedale Santissima Trinità, Cagliari, Italy

and more 21 locations

A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis

Completed
Conditions
Psoriasis
Interventions
First Posted Date
2020-06-19
Last Posted Date
2024-01-05
Lead Sponsor
Janssen-Cilag S.p.A.
Target Recruit Count
356
Registration Number
NCT04439526
Locations
🇮🇹

Policlinico di Bari Ospedale Giovanni XXIII, Bari, Italy

🇮🇹

Policlinico Sant'Orsola Malpighi, Bologna, Italy

🇮🇹

Ospedale San Giovanni di Dio, Cagliari, Italy

and more 35 locations

A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting

Completed
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
First Posted Date
2018-10-25
Last Posted Date
2022-01-03
Lead Sponsor
Janssen-Cilag S.p.A.
Target Recruit Count
312
Registration Number
NCT03720561
Locations
🇮🇹

Ospedali Riuniti Di Ancona, Ancona, Italy

🇮🇹

U.O.C. Ematologia e Terapia Cellulare Ospedale C e G Mazzoni, Ascoli Piceno, Italy

🇮🇹

U.O. Ematologia con Trapianto- AOU Policlinico di Bari, Bari, Italy

and more 36 locations

An Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricitabine and Tenofovir Alafenamide Fumarate

Completed
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Drug: D/C/F/TAF Fixed-Dose Combination (FDC)
First Posted Date
2018-07-05
Last Posted Date
2024-10-14
Lead Sponsor
Janssen-Cilag S.p.A.
Target Recruit Count
246
Registration Number
NCT03577470
Locations
🇮🇹

A O Universitaria Senese Ospedale Santa Maria alle Scotte, Siena, Italy

🇮🇹

Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

🇮🇹

Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy

and more 15 locations
  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.